Design, synthesis and biological evaluation of novel diphenylamine analogues as NLRP3 inflammasome inhibitors

被引：0

作者：

Kang, Tongtong ^{[1
]}

Sun, Simin ^{[1
]}

Wang, Huimin ^{[1
]}

Liu, Jinyu ^{[1
]}

Li, Xiaoyang ^{[1
,2
,3
]}

Jiang, Yuqi ^{[1
,2
,3
]}

机构：

[1] Ocean Univ China, Sch Med & Pharm, Key Lab Marine Drugs, Chinese Minist Educ, 5 Yushan Rd, Qingdao 266003, Peoples R China

[2] Ocean Univ China, Ctr Targeted Prot Degradat & Drug Discovery, Qingdao 266003, Shandong, Peoples R China

[3] Marine Biomed Res Inst Qingdao, Qingdao 266071, Shandong, Peoples R China

来源：

BIOORGANIC & MEDICINAL CHEMISTRY | 2024年 / 113卷

基金：

中国国家自然科学基金;

关键词：

NLRP3; inhibitors; Diphenylamine; inflammasome; Anti-inflammatory; Pyroptosis; POTENTIAL TREATMENT;

D O I：

10.1016/j.bmc.2024.117927

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The aberrant activation of the NLRP3 inflammasome has been implicated in the pathogenesis of numerous inflammation-related diseases. Development of NLRP3 inflammasome inhibitors is expected to provide a new strategy for the treatment of these diseases. Herein, a novel series of diphenylamine derivatives were designed based on the lead compounds H20 and H28, and the preliminary structure-activity relationship was studied. The representative compound 19 displayed significantly higher inhibitory activity against NLRP3 inflammasome compared to lead compounds H20 and H28, with an IC50 of 0.34 mu M. Mechanistic studies indicated that compound 19 directly targets the NLRP3 protein (K-D: 0.45 mu M), blocking the assembly and activation of the NLRP3 inflammasome, leading to anti-inflammatory effects and inhibition of cellular pyroptosis. Our findings indicated that compound 19 is a promising NLRP3 inhibitor and could potentially serve as a lead compound for further optimization.

引用

页数：16

共 45 条

[31] Overcoming Preclinical Safety Obstacles to Discover (S)-N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (GDC-2394): A Potent and Selective NLRP3 Inhibitor [J].

Townsend, Michael J. ;

Stivala, Craig E. ;

McBride, Christopher ;

Trzoss, Lynnie ;

Povero, Davide ;

Lazic, Milos ;

Ambrus-Aikelin, Geza ;

Santini, Angelina ;

Pranadinata, Rama ;

Bain, Gretchen ;

Stansfield, Ryan ;

Stafford, Jeffrey A. ;

Veal, James ;

Takahashi, Ryan ;

Ly, Justin ;

Chen, Shu ;

Liu, Liling ;

Nespi, Marika ;

Blake, Robert ;

Katewa, Arna ;

Kleinheinz, Tracy ;

Sujatha-Bhaskar, Swathi ;

Ramamoorthi, Nandhini ;

Sims, Jessica ;

McKenzie, Brent ;

Chen, Mark ;

Ultsch, Mark ;

Johnson, Matthew ;

Murray, Jeremy ;

Ciferri, Claudio ;

Staben, Steven T. . .

JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (21) :14721-14739

[32] The role of NLRP3 inflammasome in colorectal cancer: potential therapeutic target [J].

Vafaei, Somayeh ;

Taheri, Hamed ;

Hajimomeni, Yasamin ;

Yaseri, Amirhossein Fakhre ;

Zadeh, Firoozeh Abolhasani .

CLINICAL & TRANSLATIONAL ONCOLOGY, 2022, 24 (10) :1881-1889

[33] Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets [J].

Vande Walle, Lieselotte ;

Lamkanfi, Mohamed .

NATURE REVIEWS DRUG DISCOVERY, 2024, 23 (01) :43-66

[34] Discovery of Potent, Orally Bioavailable, Tricyclic NLRP3 Inhibitors [J].

Velcicky, Juraj ;

Janser, Philipp ;

Gommermann, Nina ;

Brenneisen, Silke ;

Ilic, Slavica ;

Vangrevelinghe, Eric ;

Stiefl, Nikolaus ;

Boettcher, Andreas ;

Arnold, Christelle ;

Malinverni, Claire ;

Dawson, Janet ;

Murgasova, Renata ;

Desrayaud, Sandrine ;

Beltz, Karen ;

Hinniger, Alexandra ;

Dekker, Carien ;

Farady, Christopher J. ;

Mackay, Angela .

JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (02) :1544-1562

[35] Cryo-EM structures of the active NLRP3 inflammasome disc [J].

Xiao, Le ;

Magupalli, Venkat Giri ;

Wu, Hao .

NATURE, 2023, 613 (7944) :595-+

[36] Development of sulfonamide-based NLRP3 inhibitors: Further modifications and optimization through structure-activity relationship studies [J].

Xu, Yiming ;

Xu, Yulong ;

Blevins, Hallie ;

Guo, Chunqing ;

Biby, Savannah ;

Wang, Xiang-Yang ;

Wang, Changning ;

Zhang, Shijun .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 238

[37] NLRP3 Inflammasome Inhibitor Ameliorates Amyloid Pathology in a Mouse Model of Alzheimer's Disease [J].

Yin, Jun ;

Zhao, Fanpeng ;

Chojnacki, Jeremy E. ;

Fulp, Jacob ;

Klein, William L. ;

Zhang, Shijun ;

Zhu, Xiongwei .

MOLECULAR NEUROBIOLOGY, 2018, 55 (03) :1977-1987

[38] Berberine Directly Targets the NEK7 Protein to Block the NEK7-NLRP3 Interaction and Exert Anti-inflammatory Activity [J].

Zeng, Qingxuan ;

Deng, Hongbin ;

Li, Yinghong ;

Fan, Tianyun ;

Liu, Yang ;

Tang, Sheng ;

Wei, Wei ;

Liu, Xiaojia ;

Guo, Xixi ;

Jiang, Jiandong ;

Wang, Yanxiang ;

Song, Danqing .

JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (01) :768-781

[39] Targeting NLRP3 signaling by a novel-designed sulfonylurea compound for inhibition of microglial inflammation [J].

Zhang, Changwen ;

Sajith, Ayyiliath M. ;

Xu, Xiaotian ;

Jiang, Jianxiong ;

Bowen, J. Phillip ;

Kulkarni, Amol ;

Hao, Jiukuan .

BIOORGANIC & MEDICINAL CHEMISTRY, 2022, 58

[40] Sorbremnoids A and B: NLRP3 Inflammasome Inhibitors Discovered from Spatially Restricted Crosstalk of Biosynthetic Pathways [J].

Zhang, Kaijin ;

Liu, Junyu ;

Jiang, Yuqi ;

Sun, Simin ;

Wang, Rongrong ;

Sun, Jingxian ;

Ma, Chuanteng ;

Chen, Yinghan ;

Wang, Wenxue ;

Hou, Xuewen ;

Zhu, Tianjiao ;

Zhang, Guojian ;

Che, Qian ;

Keyzers, Robert A. ;

Liu, Ming ;

Li, Dehai .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2024, 146 (26) :18172-18183

← 1 2 3 4 5 →